Spinal cord astrocytoma: response to PCV chemotherapy.
Information regarding the value of chemotherapy for spinal cord astrocytomas that progress after irradiation is limited. We describe a patient whose conus medullaris astrocytoma responded to PCV (procarbazine, lomustine, and vincristine) chemotherapy after failing radiation and cisplatin-based chemotherapy. PCV should be considered in patients with progressive spinal cord astrocytomas.
Henson
J W
JW
Brain Tumor Center, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA. henson@helix.mgh.harvard.edu
Thornton
A F
AF
Louis
D N
DN
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001254:Astrocytoma / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D001706:Biopsy; D017809:Fatal Outcome; D006801:Humans; D008130:Lomustine / Q000008:administration & dosage; D008279:Magnetic Resonance Imaging; D008297:Male; D011344:Procarbazine / Q000008:administration & dosage; D013120:Spinal Cord Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D017211:Treatment Failure; D014750:Vincristine / Q000008:administration & dosage
D011344:Procarbazine; D014750:Vincristine; D008130:Lomustine